Your Messages Inbox
Your Article Summary
See Latest ArticlesCell Therapeutics Satisfies NASDAQ Listing Requirements to Continue to Trade on NASDAQ Capital Market
Cell Therapeutics, 04/06/09
Cell Therapeutics, Inc. announced that on April 2009, CTI received notice from The NASDAQ Stock Market indicating that the company has evidenced full compliance with all applicable requirements for continued listing on The NASDAQ Capital Market. The notice followed CTI's compliance with the minimum $35 million market value of listed securities requirement for a minimum of ten consecutive trading days, as required by Marketplace Rule 4310(c)(3). As of April 2009, the company's market capitalization was $113,287,573.
Today in Marketing/Media/ROI...keeping you current
Receive free subspecialty "5-minute updates" via email
Prodesses ProParaflu+(TM) Assay Cleared for US Marketing by FDA
Gen-Probe, 12/03/09
Shire and Teva Settle Litigation Concerning Supply of ADDERALL XR Authorized Generic
Shire, 12/03/09
Chugai Revises Corporate Advertisement for First Time in Four Years
Chugai Pharmaceutical Co., 11/25/09
Article Search
Sponsor